These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 28780169)

  • 1. The PMR1 pump in alpha-synuclein toxicity and neurodegeneration.
    Nikoletopoulou V; Tavernarakis N
    Neurosci Lett; 2018 Jan; 663():66-71. PubMed ID: 28780169
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Ca2+/Mn2+ ion-pump PMR1 links elevation of cytosolic Ca(2+) levels to α-synuclein toxicity in Parkinson's disease models.
    Büttner S; Faes L; Reichelt WN; Broeskamp F; Habernig L; Benke S; Kourtis N; Ruli D; Carmona-Gutierrez D; Eisenberg T; D'hooge P; Ghillebert R; Franssens V; Harger A; Pieber TR; Freudenberger P; Kroemer G; Sigrist SJ; Winderickx J; Callewaert G; Tavernarakis N; Madeo F
    Cell Death Differ; 2013 Mar; 20(3):465-77. PubMed ID: 23154387
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rescuing defective vesicular trafficking protects against alpha-synuclein toxicity in cellular and animal models of Parkinson's disease.
    Lashuel HA; Hirling H
    ACS Chem Biol; 2006 Aug; 1(7):420-4. PubMed ID: 17168518
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Activation of β-Glucocerebrosidase Reduces Pathological α-Synuclein and Restores Lysosomal Function in Parkinson's Patient Midbrain Neurons.
    Mazzulli JR; Zunke F; Tsunemi T; Toker NJ; Jeon S; Burbulla LF; Patnaik S; Sidransky E; Marugan JJ; Sue CM; Krainc D
    J Neurosci; 2016 Jul; 36(29):7693-706. PubMed ID: 27445146
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Alpha-synuclein and tau: teammates in neurodegeneration?
    Moussaud S; Jones DR; Moussaud-Lamodière EL; Delenclos M; Ross OA; McLean PJ
    Mol Neurodegener; 2014 Oct; 9():43. PubMed ID: 25352339
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The effects of the novel A53E alpha-synuclein mutation on its oligomerization and aggregation.
    Lázaro DF; Dias MC; Carija A; Navarro S; Madaleno CS; Tenreiro S; Ventura S; Outeiro TF
    Acta Neuropathol Commun; 2016 Dec; 4(1):128. PubMed ID: 27938414
    [TBL] [Abstract][Full Text] [Related]  

  • 7. PMR1/SPCA Ca2+ pumps and the role of the Golgi apparatus as a Ca2+ store.
    Wuytack F; Raeymaekers L; Missiaen L
    Pflugers Arch; 2003 May; 446(2):148-53. PubMed ID: 12739151
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Protein Partners of α-Synuclein in Health and Disease.
    Lassen LB; Reimer L; Ferreira N; Betzer C; Jensen PH
    Brain Pathol; 2016 May; 26(3):389-97. PubMed ID: 26940507
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Is alpha-synuclein pathology a target for treatment of neurodegenerative disorders?
    Windisch M; Wolf HJ; Hutter-Paier B; Hofmeister A; Wronski R
    Curr Alzheimer Res; 2007 Sep; 4(4):446-57. PubMed ID: 17908049
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Neuropathology, biochemistry, and biophysics of alpha-synuclein aggregation.
    Uversky VN
    J Neurochem; 2007 Oct; 103(1):17-37. PubMed ID: 17623039
    [TBL] [Abstract][Full Text] [Related]  

  • 11. ESCRT components regulate the expression of the ER/Golgi calcium pump gene PMR1 through the Rim101/Nrg1 pathway in budding yeast.
    Zhao Y; Du J; Xiong B; Xu H; Jiang L
    J Mol Cell Biol; 2013 Oct; 5(5):336-44. PubMed ID: 23933635
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rab1A over-expression prevents Golgi apparatus fragmentation and partially corrects motor deficits in an alpha-synuclein based rat model of Parkinson's disease.
    Coune PG; Bensadoun JC; Aebischer P; Schneider BL
    J Parkinsons Dis; 2011; 1(4):373-87. PubMed ID: 23939344
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Alpha-synuclein misfolding and neurodegenerative diseases.
    Uversky VN
    Curr Protein Pept Sci; 2008 Oct; 9(5):507-40. PubMed ID: 18855701
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Neuropathology of synuclein aggregates.
    Duda JE; Lee VM; Trojanowski JQ
    J Neurosci Res; 2000 Jul; 61(2):121-7. PubMed ID: 10878583
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A molecular pathway of neurodegeneration linking alpha-synuclein to ApoE and Abeta peptides.
    Gallardo G; Schlüter OM; Südhof TC
    Nat Neurosci; 2008 Mar; 11(3):301-8. PubMed ID: 18297066
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Parkinson's disease and alpha synuclein: is Parkinson's disease a prion-like disorder?
    Olanow CW; Brundin P
    Mov Disord; 2013 Jan; 28(1):31-40. PubMed ID: 23390095
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Neuropathological spectrum of synucleinopathies.
    Jellinger KA
    Mov Disord; 2003 Sep; 18 Suppl 6():S2-12. PubMed ID: 14502650
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mechanisms and models of alpha-synuclein-related neurodegeneration.
    Springer W; Kahle PJ
    Curr Neurol Neurosci Rep; 2006 Sep; 6(5):432-6. PubMed ID: 16928354
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Golgi-localized, gamma ear-containing, ARF-binding (GGA) protein family alters alpha synuclein (α-syn) oligomerization and secretion.
    von Einem B; Eschbach J; Kiechle M; Wahler A; Thal DR; McLean PJ; Weishaupt JH; Ludolph AC; von Arnim CAF; Danzer KM
    Aging (Albany NY); 2017 Jul; 9(7):1677-1697. PubMed ID: 28722658
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Protein aggregation and neurodegeneration in prototypical neurodegenerative diseases: Examples of amyloidopathies, tauopathies and synucleinopathies.
    Bourdenx M; Koulakiotis NS; Sanoudou D; Bezard E; Dehay B; Tsarbopoulos A
    Prog Neurobiol; 2017 Aug; 155():171-193. PubMed ID: 26209472
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.